-+ 0.00%
-+ 0.00%
-+ 0.00%

Cartesian Therapeutics secures up to $150 million credit facility from K2 HealthVentures

PUBT·05/26/2026 11:01:46
Listen to the news
Cartesian Therapeutics secures up to $150 million credit facility from K2 HealthVentures
  • Cartesian Therapeutics entered a credit facility with K2 HealthVentures for up to USD 150 million in non-dilutive financing.
  • USD 50 million initial term loan funded at signing; proceeds extend cash runway into 2028.
  • Second USD 25 million tranche available Jan. 1–Dec. 1, 2027, subject to specified clinical and financing milestones.
  • Third USD 25 million tranche available Jan. 1–June 1, 2028, subject to specified approval and sales milestones.
  • Additional USD 50 million tranche available at Cartesian’s option, subject to K2 HealthVentures’ discretion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cartesian Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260700PRIMZONEFULLFEED9725632) on May 26, 2026, and is solely responsible for the information contained therein.